Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Revista
Intervalo de año de publicación
1.
Gut ; 69(3): 578-590, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31792136

RESUMEN

OBJECTIVE: The functional role of interleukin-22 (IL22) in chronic inflammation is controversial, and mechanistic insights into how it regulates target tissue are lacking. In this study, we evaluated the functional role of IL22 in chronic colitis and probed mechanisms of IL22-mediated regulation of colonic epithelial cells. DESIGN: To investigate the functional role of IL22 in chronic colitis and how it regulates colonic epithelial cells, we employed a three-dimentional mini-gut epithelial organoid system, in vivo disease models and transcriptomic datasets in human IBD. RESULTS: As well as inducing transcriptional modules implicated in antimicrobial responses, IL22 also coordinated an endoplasmic reticulum (ER) stress response transcriptional programme in colonic epithelial cells. In the colon of patients with active colonic Crohn's disease (CD), there was enrichment of IL22-responsive transcriptional modules and ER stress response modules. Strikingly, in an IL22-dependent model of chronic colitis, targeting IL22 alleviated colonic epithelial ER stress and attenuated colitis. Pharmacological modulation of the ER stress response similarly impacted the severity of colitis. In patients with colonic CD, antibody blockade of IL12p40, which simultaneously blocks IL12 and IL23, the key upstream regulator of IL22 production, alleviated the colonic epithelial ER stress response. CONCLUSIONS: Our data challenge perceptions of IL22 as a predominantly beneficial cytokine in IBD and provide novel insights into the molecular mechanisms of IL22-mediated pathogenicity in chronic colitis. Targeting IL22-regulated pathways and alleviating colonic epithelial ER stress may represent promising therapeutic strategies in patients with colitis. TRIAL REGISTRATION NUMBER: NCT02749630.


Asunto(s)
Colitis/genética , Enfermedad de Crohn/fisiopatología , Estrés del Retículo Endoplásmico/genética , Células Epiteliales/fisiología , Interleucinas/farmacología , Transcripción Genética , Animales , Antibacterianos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/genética , Supervivencia Celular/efectos de los fármacos , Enfermedad Crónica , Colitis/sangre , Colitis/tratamiento farmacológico , Colitis/patología , Colon/patología , Enfermedad de Crohn/patología , Modelos Animales de Enfermedad , Estrés del Retículo Endoplásmico/efectos de los fármacos , Fármacos Gastrointestinales/farmacología , Fármacos Gastrointestinales/uso terapéutico , Humanos , Interleucina-17/farmacología , Interleucina-23/antagonistas & inhibidores , Interleucinas/sangre , Interleucinas/genética , Mucosa Intestinal/patología , Ratones , Organoides , Gravedad del Paciente , Fenilbutiratos/farmacología , Proteínas Recombinantes/farmacología , Transcripción Genética/efectos de los fármacos , Tunicamicina/farmacología , Respuesta de Proteína Desplegada , Ustekinumab/farmacología , Ustekinumab/uso terapéutico , Interleucina-22
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA